Pablo Miguel
Barreiro García
Publicacións nas que colabora con Pablo Miguel Barreiro García (17)
2023
-
Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions
Journal of Clinical Virology, Vol. 167
2020
-
Hospital admissions in individuals with HTLV-1 infection in Spain
AIDS, Vol. 34, Núm. 7, pp. 1019-1027
2019
-
Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain
Journal of Antimicrobial Chemotherapy, Vol. 74, Núm. 5, pp. 1357-1362
-
Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain
Open Forum Infectious Diseases, Vol. 6, Núm. 2
-
HTLV testing of solid organ transplant donors
Clinical Transplantation
-
HTLV-1 infection in solid organ transplant donors and recipients in Spain
BMC Infectious Diseases, Vol. 19, Núm. 1
2018
-
Decline and changing profile of hepatitis delta among injection drug users in Spain
Antiviral Therapy, Vol. 23, Núm. 1, pp. 87-90
2017
-
Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 7, pp. 2083-2088
-
HIV type 2 epidemic in Spain: Challenges and missing opportunities
AIDS, Vol. 31, Núm. 10, pp. 1353-1364
-
Human T-lymphotropic virus type 1 infection and disease in Spain
AIDS, Vol. 31, Núm. 12, pp. 1653-1663
-
Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach
PLoS ONE, Vol. 12, Núm. 9
2016
-
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013
Journal of Infection, Vol. 72, Núm. 5, pp. 587-596
-
MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression
PLoS ONE, Vol. 11, Núm. 5
2014
-
Very late HCV relapse following triple therapy for hepatitis C
Antiviral Therapy
2013
-
Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B
AIDS, Vol. 27, Núm. 14, pp. 2219-2224
-
Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir
Antiviral Therapy, Vol. 18, Núm. 5, pp. 709-715